The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection
批准号:
9225159
负责人:
Mark Daniel Hicar
金额:
$39.17万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-16 至 2021-01-31
关键词:
Acquired Immunodeficiency SyndromeAffectAntibodiesAntibody ResponseAntibody titer measurementAntigen TargetingAntigensB-LymphocytesBindingBiological AssayBiological ModelsCaringCell TherapyClinicClinical DataCollaborationsComplexDataDevelopmentElectrophoretic Mobility Shift AssayEnzyme-Linked Immunosorbent AssayEpitopesFutureHIVHIV AntibodiesHIV AntigensHIV InfectionsImmunologicsIndividualInfectionInfusion proceduresKnowledgeMacacaMasksMeasuresMethodsModelingMolecular ConformationMutateNew YorkPharmacologyPilot ProjectsPlayPrevalenceReagentRecombinantsRecruitment ActivityRoleSamplingSerumSpecificityStructureSurfaceSurface Plasmon ResonanceTestingTherapeuticVaccine DesignVaccinesViralViremiaantibody-dependent cell cytotoxicityantigen bindingarmbasecohortenv Gene Productsexperimental studyimmune functionimmunogenicimmunogenicityneutralizing antibodynovelpassive antibodiesprematurepublic health relevanceresponsesimian human immunodeficiency virussuccesstherapeutic vaccinevaccine candidatevaccine trial
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Of the 35 million living with HIV in the world today, small percentages have never received therapy but retain adequate CD4 help and resist progression to AIDS. To date, the immunological constraints leading to this so-called long-term non-progression (LTNP) state remain largely unknown. Certain non-neutralizing antibodies (Abs) have shown protection and control in HIV challenge model systems and the non-neutralizing antibody-dependent cell-cytotoxicity function is thought to play a role in protection seen in the recent RV144 vaccine `Thai Trial'.We have previously isolated a number of non-neutralizing Abs from LTNP subjects' B cells that target two non-linear conformational trimer-dependent epitopes in the HIV surface envelope protein gp41. In preliminary studies these epitopes are present on advanced vaccine candidates that replicate the native surface HIV envelope trimer. In preliminary serum competition studies, targeting of these gp41 non-linear conformational trimer dependent epitopes is more prevalent in LTNP subjects; with 50- 75% of LTNP subjects having high Ab titers. We hypothesize that Abs targeting these non-linear conformational trimer dependent epitopes assist in maintaining the LTNP state by functional targeting of native surface envelope structure. To explore rates of epitope targeting in LTNP subjects, we will recruit a larger number (45 minimum in each arm) of LTNP to compare levels to progressing subjects, maintained on therapy, and HIV negative control samples. We have established collaborations at HIV care clinics across New York State. To measure binding of these structurally targeted Abs to a panel of HIV antigens including proposed vaccine constructs, we will recombinantly express a panel of HIV antigens containing gp41 epitopes. This panel will include leading vaccine candidates and mutated forms of antigen to confirm specificity of binding. ELISA based assays, native gel shift assays and surface plasmon resonance will be used to confirm binding and characterize the specificity of targeted antigen. To identify the function of these Abs in assisting the LTNP state, we will test antibody dependent cell cytotoxicity by these Abs. By fully characterizing the non-linear conformational trimer dependent Abs and their targets, we will provide the basis for future immunogenicity studies to test if these epitopes can assist in protection or control.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection
-
批准号:9140860
-
项目类别:
-
资助金额:$39.19万
-
财政年份:2016
-
负责人:Mark Daniel Hicar
-
依托单位:
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)
-
批准号:8118142
-
项目类别:
-
资助金额:$12.78万
-
财政年份:2009
-
负责人:Mark Daniel Hicar
-
依托单位:
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)
-
批准号:8526356
-
项目类别:
-
资助金额:$12.78万
-
财政年份:2009
-
负责人:Mark Daniel Hicar
-
依托单位:
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)
-
批准号:8517305
-
项目类别:
-
资助金额:$12.78万
-
财政年份:2009
-
负责人:Mark Daniel Hicar
-
依托单位:
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)
-
批准号:7686410
-
项目类别:
-
资助金额:$12.78万
-
财政年份:2009
-
负责人:Mark Daniel Hicar
-
依托单位:
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)
-
批准号:7936069
-
项目类别:
-
资助金额:$12.78万
-
财政年份:2009
-
负责人:Mark Daniel Hicar
-
依托单位:
海外基金